[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2013184900A3 - Immunogenic compositions and related methods - Google Patents

Immunogenic compositions and related methods Download PDF

Info

Publication number
WO2013184900A3
WO2013184900A3 PCT/US2013/044488 US2013044488W WO2013184900A3 WO 2013184900 A3 WO2013184900 A3 WO 2013184900A3 US 2013044488 W US2013044488 W US 2013044488W WO 2013184900 A3 WO2013184900 A3 WO 2013184900A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune response
subject
polypeptides
immunogenic compositions
staphylococci
Prior art date
Application number
PCT/US2013/044488
Other languages
French (fr)
Other versions
WO2013184900A2 (en
Inventor
Hubert LAM
Jeremy Yethon
Original Assignee
Sanofi Pasteur Biologics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics, Llc filed Critical Sanofi Pasteur Biologics, Llc
Publication of WO2013184900A2 publication Critical patent/WO2013184900A2/en
Publication of WO2013184900A3 publication Critical patent/WO2013184900A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This disclosure relates to polypeptides that may be used as immunogens in immunogenic compositions (e.g., vaccines) for eliciting an immune response in a subject against staphylococci (such as coagulase-negative staphylococci (CoNS) and/or S. aureus species). The immune response elicited (e.g., antibodies) inhibits biofilm development and may be sufficient for treating and/or preventing disease resulting from an infection by a Staphylococcus species. Binding agents that bind to these polypeptides are also provided. Exemplary polypeptides include but are not limited to SEQ ID NOs: 1-38 and fragments and derivatives thereof. Immunogenic compositions including one or more polypeptides are provided, as are methods for their use (e.g., to induce an immune response to staphylococci in a subject by administering to the subject a composition as described herein). Administration of the compositions of the present disclosure to a subject may elicit an immune response against a number of Staphylococcus species and/or strains.
PCT/US2013/044488 2012-06-06 2013-06-06 Immunogenic compositions and related methods WO2013184900A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656427P 2012-06-06 2012-06-06
US61/656,427 2012-06-06

Publications (2)

Publication Number Publication Date
WO2013184900A2 WO2013184900A2 (en) 2013-12-12
WO2013184900A3 true WO2013184900A3 (en) 2014-09-04

Family

ID=48917675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/044488 WO2013184900A2 (en) 2012-06-06 2013-06-06 Immunogenic compositions and related methods

Country Status (1)

Country Link
WO (1) WO2013184900A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004025416A2 (en) * 2002-09-13 2004-03-25 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
WO2004087746A2 (en) * 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
WO2006032472A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
US20070037163A1 (en) * 1997-08-14 2007-02-15 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
AR054822A1 (en) 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa EMULSION OIL IN THERMOREVERSIBLE WATER
CN101801343A (en) 2007-07-26 2010-08-11 圣诺菲·帕斯图尔有限公司 antigen-adjuvant compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037163A1 (en) * 1997-08-14 2007-02-15 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics
WO2004025416A2 (en) * 2002-09-13 2004-03-25 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
WO2004087746A2 (en) * 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
WO2006032472A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 15 February 2005 (2005-02-15), "SubName: Full=Phosphonate ABC transporter, phosphonate-binding protein;", XP002718822, retrieved from EBI accession no. UNIPROT:Q5HKQ7 Database accession no. Q5HKQ7 *
GILL STEVEN R ET AL: "Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC; US, vol. 187, no. 7, 1 April 2005 (2005-04-01), pages 2426 - 2438, XP002463146, ISSN: 0021-9193, DOI: 10.1128/JB.187.7.2426-2438.2005 *
TIM EBERT ET AL: "Development of a rat central venous catheter model for evaluation of vaccines to prevent Staphylococcus epidermidis and Staphylococcus aureus early biofilms", HUMAN VACCINES, vol. 7, no. 6, 1 June 2011 (2011-06-01), pages 630 - 638, XP055095946, ISSN: 1554-8600, DOI: 10.4161/hv.7.6.15407 *
VAN MELLAERT LIEVE ET AL: "Immunoprophylaxis and immunotherapy of Staphylococcus epidermidis infections: challenges and prospects", EXPERT REVIEW OF VACCINES ENGLAND MAR 2009, EXPERT REVIEWS LTD, GB, vol. 11, no. 3, 1 March 2012 (2012-03-01), pages 319 - 334, XP009175495, ISSN: 1744-8395, DOI: 10.1586/ERV.11.190 *

Also Published As

Publication number Publication date
WO2013184900A2 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
WO2014089169A3 (en) Immunotherapy with binding agents
MY185139A (en) Substituted imidazopyridazines
WO2012058393A3 (en) Dkk1 antibodies and methods of use
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
WO2014031610A8 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2012003058A (en) Vaccines directed to langerhans cells.
ZA201200832B (en) Immunogenic composition comprising antigenic s. aureus proteins
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MY168413A (en) Amino-substituted imidazopyridazines
UA118332C2 (en) Cs27l antigen binding proteins
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX364623B (en) MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2010089554A8 (en) Grass peptides for vaccine
IN2014DN09445A (en)
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2007008904A3 (en) Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
WO2014144222A3 (en) Compositions and methods of treating fungal and bacterial pathogens
WO2013184900A3 (en) Immunogenic compositions and related methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13745485

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13745485

Country of ref document: EP

Kind code of ref document: A2